RPID - NASDAQ

Rapid Micro Biosystems, Inc.

Rapid Micro Biosystems, Inc.

RPID·NASDAQ

$2.00

+1.8%
HealthcareMedical - Devices

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in North America, Europe, and Asia. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and comprehensive customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides installation and verification, technical training, and support services. Its solutions are used in environmental monitoring, water testing, bioburden, and sterility release testing applications. The company was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. Rapid Micro Biosystems, Inc. was incorporated in 2006 and is headquartered in Lowell, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$90.42M
EPS-1.0500
P/E Ratio-1.90
Earnings Date07/31/2026
-31.06M
Operating Cash Flow
-30%
3Y-47.0%
5Y-
10Y+47.0%
14.33M
Investing Cash Flow
-61%
3Y-115.0%
5Y-191.0%
10Y-945.0%
19.77M
Financing Cash Flow
9639%
3Y+2753.0%
5Y-69.0%
10Y+33.0%
RPID

Rapid Micro Biosystems, Inc. Cash Conversion Engine

RPID · NASDAQ
Net Income-47.12M
Depreciation & Amortization3.25M
Stock-Based Compensation4.03M
Change in Working Capital6.06M
Others2.71M
Capital Expenditures-850.00K
Free Cash Flow-31.91M

Cash Flow Quality Analysis

FCF Conversion Rate

67.7%

Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.

CapEx Intensity

-2.7%

Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.

FCF Growth Trend

+29.9%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

+$6.06M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Rapid Micro Biosystems, Inc. Cash Flow Statement

RPID • NASDAQ

Rapid Micro Biosystems, Inc. Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
OPERATING ACTIVITIES
Net Income
-47.1M
-46.9M
-52.5M
-60.8M
-73.5M
-37.1M
-21.2M
Depreciation & Amortization
3.3M
3.4M
3.1M
2.8M
1.5M
1.5M
1.5M
Change in Deferred Taxes
0.0
0.0
0.0
0.0
0.0
0.0
-249K
Stock-Based Compensation
4M
3.9M
4.8M
4M
1.8M
533K
473K
Other Non-Cash Items
2.7M
271K
-1M
728K
23.2M
5.1M
449K
Change in Working Capital
6.1M
-4.8M
555K
-5.3M
-8M
-1.1M
-2.1M
Cash from Operating Activities
-31.1M
-44.2M
-45.1M
-58.5M
-55M
-31M
-21.1M
INVESTING ACTIVITIES
Investments in Property, Plant, and Equipment
-850K
-1.4M
-1.8M
-6.7M
-3.2M
-690K
-1.7M
Purchase of Investments
-27.1M
-35M
-62.5M
-179.2M
-25.1M
-25M
(0.0)
Sale/Maturity of Investments
42.3M
73.1M
106.5M
92.5M
15M
10M
0.0
Other Investing Items
0.0
0.0
0.0
0.0
20K
0.0
0.0
Cash from Investing Activities
(14.3M)
(36.7M)
(42.2M)
-93.5M
-13.3M
-15.7M
-1.7M
FINANCING ACTIVITIES
Net Issuance of Common Stock
1.1M
238K
0.0
0.0
164.1M
0.0
11K
Net Issuance of Debt
19.1M
-35K
-37K
-33K
-26.2M
16.5M
0.0
Other Financing Items
-419K
0.0
186K
726K
-940K
-2.2M
0.0
Cash from Financing Activities
19.8M
203K
149K
693K
216.7M
64.2M
14.9M
CASH FLOW SUMMARY
Effect of Foreign Exchange Rates
0.0
-81K
0.0
0.0
0.0
0.0
0.0
Net Change in Cash
3M
-7.4M
-2.8M
-151.3M
148.5M
17.6M
-8M
Cash at Beginning of Period
17.3M
24.3M
27.3M
178.7M
30.2M
12.6M
20.6M
Cash at End of Period
20.3M
16.9M
24.6M
27.3M
178.7M
30.2M
12.6M
Free Cash Flow
-31.9M
-45.5M
-46.9M
-65.3M
-58.2M
-31.7M
-22.8M

SEC Filings

RPID - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 28, 2026
May 21, 2026
2026
View Filing
8-K

8-K 2026

N/A

May 19, 2026
May 18, 2026
2026
View Filing
10-Q

10-Q 2026 Q1

Q1

May 15, 2026
March 31, 2026
2026
View Filing
8-K

8-K 2026

N/A

May 13, 2026
May 13, 2026
2026
View Filing
DEF 14A

DEF 14A 2026

N/A

April 08, 2026
May 21, 2026
2026
View Filing
8-K

8-K 2026

N/A

March 27, 2026
March 23, 2026
2026
View Filing
8-K

8-K 2026

N/A

March 12, 2026
March 12, 2026
2026
View Filing
10-K

10-K 2025 FY

FY

March 12, 2026
December 31, 2025
2025
View Filing
8-K

8-K 2026

N/A

January 13, 2026
January 13, 2026
2026
View Filing
10-Q

10-Q 2025 Q3

Q3

November 07, 2025
September 30, 2025
2025
View Filing
Showing 1 to 10 of 75 filings

Related Guides

Blog Categories

Continue your RPID research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.